To evaluate AD pathology, we have used a commonly used proxy for in vivo AD pathology [9]: a cerebrospinal fluid (CSF) biomarker profile indicative of amyloid deposition (A), tau accumulation (T), and neurodegeneration (N) [10]. The gene discussed is MAPT; the disease is Alzheimer disease.